[Federal Register Volume 83, Number 134 (Thursday, July 12, 2018)]
[Notices]
[Page 32301]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-14943]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2018-N-2642]
Advisory Committee; Science Advisory Board to the National Center
for Toxicological Research; Renewal
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; renewal of advisory committee.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
renewal of the Science Advisory Board (the Board) to the National
Center for Toxicological Research (NCTR) by the Commissioner of Food
and Drugs (the Commissioner). The Commissioner has determined that it
is in the public interest to renew the Board to the NCTR for an
additional 2 years beyond the charter expiration date. The new charter
will be in effect until June 2, 2020.
DATES: Authority for the Board to the NCTR expired on June 2, 2018;
however, the Commissioner formally determined that renewal is in the
public interest.
FOR FURTHER INFORMATION CONTACT: Donna L. Mendrick, National Center for
Toxicological Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 32, Rm. 2208, Silver Spring, MD 20993-0002, 301-
796-8892, [email protected].
SUPPLEMENTARY INFORMATION: Pursuant to 41 CFR 102-3.65 and approval by
the Department of Health and Human Services pursuant to 45 CFR part 11
and by the General Services Administration, FDA is announcing the
renewal of the Board to the NCTR. The Board is a discretionary Federal
advisory committee established to provide advice to the Commissioner.
The Board to the NCTR advises the Commissioner or designee in
discharging responsibilities as they relate to helping to ensure safe
and effective drugs for human use and, as required, any other product
for which FDA has regulatory responsibility. The Board advises the NCTR
Director in establishing, implementing, and evaluating the research
programs that assist the Commissioner in fulfilling regulatory
responsibilities. The Board provides an extra-agency review in ensuring
that the research programs at NCTR are scientifically sound and
pertinent.
The Board shall consist of a core of nine voting members including
the Chair. Members and the Chair are selected by the Commissioner or
designee from among authorities knowledgeable in the fields of
toxicological research. Members will be invited to serve for
overlapping terms of up to 4 years. Almost all non-Federal members of
this Board serve as Special Government Employees. The core of voting
members may include one technically qualified member, selected by the
Commissioner or designee, who is identified with consumer interests and
is recommended by either a consortium of consumer-oriented
organizations or other interested persons.
Further information regarding the most recent charter and other
information can be found at https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/ToxicologicalResearch/ucm148166.htm or by
contacting the Designated Federal Officer (see FOR FURTHER INFORMATION
CONTACT). In light of the fact that no change has been made to the
committee name or description of duties, no amendment will be made to
21 CFR 14.100.
This document is issued under the Federal Advisory Committee Act (5
U.S.C. app.). For general information related to FDA advisory
committees, please check https://www.fda.gov/AdvisoryCommittees/default.htm.
Dated: July 9, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-14943 Filed 7-11-18; 8:45 am]
BILLING CODE 4164-01-P